Results 261 to 270 of about 6,836,441 (345)

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Qualitative exploration of women's experiences of vasomotor symptoms to support the content validity of patient-reported outcomes. [PDF]

J Patient Rep Outcomes
Haberland C, Barclay M, Whyman S, Lehane A, Gater A, Gerlinger C, Seitz C, Francuski M, Schoof N, Trigg A, Bradley H.   +10 more
europepmc   +1 more source

POB10 VALIDATION OF A PATIENT-REPORTED OUTCOMES QUESTIONNAIRE FOR ASSESSING POSITIVE WELL-BEING ASSOCIATED WITH BEHAVIORAL CHANGES

, 2005
X Mesrobian, Polyxane Mertzanis, S Dard
openalex   +1 more source

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Journal of the National Cancer Institute, 2014
E. Basch, B. Reeve, S. Mitchell, S. Clauser, L. Minasian, A. Dueck, T. Mendoza, J. Hay, T. Atkinson, A. Abernethy, D. Bruner, C. Cleeland, J. Sloan, Ram Chilukuri, Paul Baumgartner, A. Denicoff, D. S. St Germain, A. O'Mara, Alice Chen, J. Kelaghan, A. Bennett, L. Sit, L. Rogak, A. Barz, D. Paul, D. Schrag   +25 more
semanticscholar   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Patient-Reported Outcomes and Psychosocial Impact of Vascular Malformations in Asian Patients. [PDF]

J Clin Med
Jia H, Liu H, Yang X, Xu Z, Luo L, Zhang Y, Hua C, Lin X.   +7 more
europepmc   +1 more source

PCV19 A LITERATURE REVIEW OF PATIENT-REPORTED OUTCOMES (PRO) USED IN ATRIAL FIBRILLATION

, 2005
V Staniek, MC Minjoulat-Rey, S Gabriel, MP Emery, B Arnould, Łukasz Prost, O Bouin   +6 more
openalex   +1 more source

Patient-Reported Outcomes 1 Year After Immediate Breast Reconstruction: Results of the Mastectomy Reconstruction Outcomes Consortium Study.

Journal of Clinical Oncology, 2017
A. Pusic, E. Matros, N. Fine, E. Buchel, G. Gordillo, J. Hamill, Hyungjin Kim, Ji Qi, C. Albornoz, A. Klassen, E. Wilkins   +10 more
semanticscholar   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source